Pre-Made Ledelabricin Alfa biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting PRG4(PROTEOGLYCAN 4) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ledelabricin Alfa biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting PRG4(PROTEOGLYCAN 4) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Proteoglycan 4 or lubricin is a surface-active mucinous glycoprotein secreted in the synovial joint that plays an important role in cartilage integrity. In healthy joints, lubricin molecules coat the cartilage surface, providing boundary lubrication and preventing cell and protein adhesion. Arthropathy occurring in patients with joint trauma, inflammatory arthritis or genetically mediated lubricin deficiencies have insufficient lubricin to prevent damage to articular cartilage. Ledelabricin Alfa is a human proteoglycan 4 isoform A variant, produced in Chinese hamster ovary (CHO) cells have been used to treat Arthropathy
| Products Name (INN Index) | Pre-Made Ledelabricin Alfa biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting PRG4(PROTEOGLYCAN 4) |
|---|---|
| INN Name | ledelabricin alfa |
| Target | PRG4(PROTEOGLYCAN 4) |
| Format | Recombinant Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | PRG4 (lubricin, cartilage superficial zone proteoglycan, megakaryocyte stimulating factor) isoform A |
| VD LC | PRG4 (lubricin, cartilage superficial zone proteoglycan, megakaryocyte stimulating factor) isoform A |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Novartis?(Basel Switzerland) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | PRG4(PROTEOGLYCAN 4) |
| Package |
